Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 17Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasm Metastasis 6Prostatic Neoplasms 5Melanoma 5Lung Neoplasms 5Solid Tumor 3Pain, Postoperative 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myeloid, Acute 3Gastrointestinal Stromal Tumors 3Colorectal Neoplasms 3Anxiety Disorders 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Pain 2Glioma 2Colonic Neoplasms 2Choledocholithiasis 2Choledochal Cyst 2Carcinoma 2Advanced Solid Tumor 2Advanced Malignancies 2cMET-dysregulated Advanced Solid Tumors 1Urothelial Cancer 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1

Interventions

Cyclophosphamide 56Cytarabine 43fludarabine phosphate 37Methotrexate 35Whole-Body Irradiation 32Mycophenolic Acid 29Filgrastim 27fludarabine 25Peripheral Blood Stem Cell Transplantation 22Vincristine 21Cyclosporine 20Busulfan 19Dexamethasone 18Specimen Handling 17Methylprednisolone 17venetoclax 16Granulocyte Colony-Stimulating Factor 16Tacrolimus 15Hydrocortisone 15Melphalan 14Daunorubicin 14Asparaginase 14merphos 13Thiotepa 13Mercaptopurine 13Leucovorin 13Cord Blood Stem Cell Transplantation 13Antilymphocyte Serum 13Calcium Dobesilate 11Biopsy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Biphenotypic, Acute × Midazolam × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡